Systemic Immune-Inflammation Index useful marker for monitoring psoriasis treatment with TNF-Alpha blockers
Systemic Immune-Inflammation Index useful marker for monitoring psoriasis treatment with TNF-Alpha blockers suggests a new study published in the Journal of Clinical Medicine.
Psoriasis is a chronic systemic inflammatory disease that can affect the skin and/or joints, affecting 2–3% of the world’s population. As in many inflammatory diseases, it is important to determine the severity of the disease for safe and effective treatment. As there is no single tool that can fully assess the severity of psoriasis, the assessment of the disease becomes more complex.Psoriasis is a chronic immune-mediated skin disease in which systemic inflammation plays an important role in its pathogenesis. In recent years, the neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-monocyte ratio (NMR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were shown to be important indicators of inflammation.
This study aimed to investigate the NLR, NMR, PLR, and SII levels in psoriasis patients treated with biological agents. Method: Clinical and biochemical data of 209 patients who received systemic therapy for psoriasis were obtained by retrospectively reviewing their medical records. The NLR, NMR, PLR, and SII values were calculated from the hemogram values of the patients. Results: In the third month of follow-up, the mean CRP, NLR, NMR, PLR, and SII values were significantly decreased compared with the baseline values. The SII values showed strong positive correlations with the NLR, NMR, and PLR. Adalimumab, etanercept, and infliximab, which are TNF-α blockers, were observed to be more effective on the PLR and NLR, and especially the NMR. Conclusions: The NLR, NMR, PLR, and SII, which are data derived from routine blood tests, can be used in the monitoring of the treatment of psoriasis, especially with TNF-α blockers.
Reference:
Albayrak H. Neutrophil-to-Lymphocyte Ratio, Neutrophil-to-Monocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index in Psoriasis Patients: Response to Treatment with Biological Drugs. Journal of Clinical Medicine. 2023; 12(17):5452. https://doi.org/10.3390/jcm12175452
